In one paragraphArticle in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
19 authors.
Laura SavariauWomens Cancer Research Center at UPMC Hillman Cancer Center and Magee Women's Research Institute, Pittsburgh, PA.ORCID 0000-0003-0452-9481 Ye QinWomens Cancer Research Center at UPMC Hillman Cancer Center and Magee Women's Research Institute, Pittsburgh, PA.
Osama ShahWomens Cancer Research Center at UPMC Hillman Cancer Center and Magee Women's Research Institute, Pittsburgh, PA.ORCID 0000-0003-4756-4535 Ahmed M BasudanWomens Cancer Research Center at UPMC Hillman Cancer Center and Magee Women's Research Institute, Pittsburgh, PA.ORCID 0000-0002-6689-7004 Chris MerkelWomens Cancer Research Center at UPMC Hillman Cancer Center and Magee Women's Research Institute, Pittsburgh, PA.ORCID 0009-0000-1987-5147 Ethan S SokolComputational Discovery, Foundation Medicine, Boston, MA.
Olivia McGinnWomens Cancer Research Center at UPMC Hillman Cancer Center and Magee Women's Research Institute, Pittsburgh, PA.ORCID 0000-0003-0769-5581 Zheqi LiWomens Cancer Research Center at UPMC Hillman Cancer Center and Magee Women's Research Institute, Pittsburgh, PA.ORCID 0000-0003-1213-640X Tiantong LiuWomens Cancer Research Center at UPMC Hillman Cancer Center and Magee Women's Research Institute, Pittsburgh, PA.
Nilgun TasdemirWomens Cancer Research Center at UPMC Hillman Cancer Center and Magee Women's Research Institute, Pittsburgh, PA.ORCID 0000-0002-8700-0251 Pooja TallapaneniWomens Cancer Research Center at UPMC Hillman Cancer Center and Magee Women's Research Institute, Pittsburgh, PA.
Lan CoffmanWomens Cancer Research Center at UPMC Hillman Cancer Center and Magee Women's Research Institute, Pittsburgh, PA.ORCID 0000-0002-3753-1652 Esther ElishaevDepartment of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA.ORCID 0000-0002-6271-0222 Jennifer M AtkinsonWomens Cancer Research Center at UPMC Hillman Cancer Center and Magee Women's Research Institute, Pittsburgh, PA.
Peter C LucasWomens Cancer Research Center at UPMC Hillman Cancer Center and Magee Women's Research Institute, Pittsburgh, PA.ORCID 0000-0003-4880-7172 Adrian V LeeWomens Cancer Research Center at UPMC Hillman Cancer Center and Magee Women's Research Institute, Pittsburgh, PA.ORCID 0000-0001-9917-514X Steffi OesterreichWomens Cancer Research Center at UPMC Hillman Cancer Center and Magee Women's Research Institute, Pittsburgh, PA.ORCID 0000-0002-2537-6923 Funding
VECTOR CORE FACILITYP30CA047904 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI CHRISTOPHER J. BAKKENIST · 1988 to 2026
$158.0MHigh-Throughput Computing for Genomics and Bioinformatics ResearchS10OD028483 · OD · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI LEE, ADRIAN V · 2021 to 2021
$574kNCI NIH HHS P30 CA047904NIH HHS S10 OD028483
6 · The paper itselfAbstract
Treatment resistance and metastases occur in 10-20% of patients with invasive lobular carcinoma (ILC), the most common special histological subtype of breast cancer. ILC metastasizes to the ovary more frequently than no special type (NST) tumors, also known as invasive ductal carcinoma (IDC). To characterize the genomic landscape of breast cancer ovarian metastases, we analyzed 15,613 local breast cancers, 22,010 non-ovarian metastases, and 246 ovarian metastases sequenced using FoundationOne
Identifiers
PMID42619866
PMCPMC13484263
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390